KORU Medical Systems, Inc. (KRMD) AI Stock Analysis

KORU Medical Systems, Inc. specializes in the design, manufacturing, and global distribution of portable medical devices tailored primarily for the ambulatory infusion market. Its core product lineup features mechanical infusion systems under the FREEDOM brand, which includes the FREEDOM60 and FreedomEdge syringe drivers, alongside HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. These products offer precise delivery of medications and therapies for diverse medical needs. The company also supplies educational and training resources for clinicians, patients, and advocates. Products are distributed worldwide through direct sales channels, distributor partnerships, and an online presence.

Annual revenue increased from $23.5M in FY2021 to $41.1M in FY2025, supported by 22.2% growth in FY2025 and 18.0% in FY2024. Over this period, gross margin improved from 58.6% in FY2021 to 62.3% in FY2025, peaking at 63.4% in FY2024. Operating margins narrowed their deficits from -38.6% in FY2022 to -7.2% in FY2025, with net income improving from -$13.7M in FY2023 to -$2.6M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 18.2% year-over-year, while quarterly earnings declined 66.0%. Trailing twelve-month operating margin turned positive at 5.2%, though trailing profit margin remained at -4.0%.

As of June 30, 2026, KORU Medical Systems held $8.3M in cash and short-term investments against total debt of $3.2M, resulting in a net cash position of $5.0M. The company maintains a current ratio of 2.72 and a debt-to-equity ratio of 0.18, backed by $18.1M in shareholders' equity. Operating cash flow improved to $462,405 in FY2025 from -$4.3M in FY2021, while free cash flow stood at -$470,112. Capital expenditures were $932,517 in FY2025, and the five-year share count change shows an increase of 11.1%.

At a market cap of $137.8M and enterprise value of $146.0M, KRMD trades at a forward P/E of 82.0x, significantly above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 3.1x sits below the peer median of 4.1x. Over the past year, KRMD shares declined 25.4%, lagging the S&P 500 (SPY) gain of 16.8%. Over a five-year period, the stock gained 4.5%, compared to an 83.0% gain for the S&P 500.

Wall Street coverage includes 3 Strong Buy ratings, 1 Hold rating, and zero Sell ratings. The mean price target is $6.25, representing a 108.3% premium over the last close of $3.00. For the fiscal year ending December 31, 2026, analysts estimate revenue of $48.0M and EPS of -$0.01. For the following fiscal year, 2 analysts project revenue of $56.3M (17.2% growth) and EPS of $0.04. Over the last 4 quarters, the company has posted 3 EPS beats. The next earnings date is November 11, 2026.

This page is an AI-written research summary of KORU Medical Systems, Inc. (KRMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KRMD income statement, KRMD balance sheet, KRMD key metrics, KRMD analyst forecast, KRMD chart. See the KRMD stock overview for the latest quote and news.